{"id":2862,"date":"2026-09-01T09:32:13","date_gmt":"2026-09-01T09:32:13","guid":{"rendered":"https:\/\/pevropeptides.com\/?post_type=product&#038;p=2862"},"modified":"2026-09-02T12:19:00","modified_gmt":"2026-09-02T12:19:00","slug":"aicar-50mg","status":"publish","type":"product","link":"https:\/\/pevropeptides.com\/cs\/product\/aicar-50mg\/","title":{"rendered":"Aicar 50 mg"},"content":{"rendered":"<p>AICAR je syntetick\u00fd nukleosidov\u00fd analog, chemicky imidazol-4-karboxamid ribonukleosid. Ve v\u011bdeck\u00e9m v\u00fdzkumu je studov\u00e1n jako modelov\u00e1 slou\u010denina pro biochemii AMP-aktivovan\u00e9 proteinkin\u00e1zy (AMPK) a jako referen\u010dn\u00ed standard v analytick\u00fdch prac\u00edch. Tato slou\u010denina je nab\u00edzena jako lyofilizovan\u00fd pr\u00e1\u0161ek o hmotnosti 50 mg na lahvi\u010dku, v\u00fdhradn\u011b pro laboratorn\u00ed a v\u00fdzkumn\u00e9 \u00fa\u010dely.<\/p>\n<h2>Co je AICAR?<\/h2>\n<p>AICAR (5-amino-1-\u03b2-D-ribofuranosylimidazol-4-karboxamid), v literatu\u0159e ozna\u010dovan\u00fd tak\u00e9 jako akadesin nebo AICA ribosid, je mal\u00e1 organick\u00e1 molekula slo\u017een\u00e1 z imidazol-4-karboxamidov\u00e9ho j\u00e1dra v\u00e1zan\u00e9ho na rib\u00f3zovou jednotku. Tato struktura z n\u011bj form\u00e1ln\u011b \u010din\u00ed nukleosidov\u00fd analog: struktura napodobuje ribonukleosidovou architekturu p\u0159irozen\u00fdch purinov\u00fdch stavebn\u00edch blok\u016f, ale li\u0161\u00ed se heterocyklickou hlavou. Tato kombinace \u2013 rozpoznateln\u00e1 u nukleosidov\u00fdch transport\u00e9r\u016f a kin\u00e1z, ale s jinou b\u00e1z\u00ed \u2013 \u010din\u00ed z t\u00e9to slou\u010deniny \u0161iroce pou\u017e\u00edvan\u00fd model p\u0159i studiu metabolismu nukleotid\u016f a regulace kin\u00e1z.<\/p>\n<p>Ve v\u00fdzkumn\u00fdch modelech slou\u017e\u00ed samotn\u00fd AICAR jako v\u00fdchoz\u00ed slou\u010denina: v bun\u011b\u010dn\u00fdch modelech je p\u0159ij\u00edm\u00e1n nukleosidov\u00fdmi transport\u00e9ry a fosforylov\u00e1n adenosinkin\u00e1zou na odpov\u00eddaj\u00edc\u00ed ribonukleotid, v literatu\u0159e ozna\u010dovan\u00fd jako ZMP. Tento nukleotid je strukturn\u011b p\u0159\u00edbuzn\u00fd AMP, a proto je popisov\u00e1n jako mimetikum AMP: in vitro se v\u00e1\u017ee na \u03b3-podjednotku AMPK a alostericky posouv\u00e1 enzym do jeho aktivn\u00ed konformace, ani\u017e by se zm\u011bnil samotn\u00fd intracelul\u00e1rn\u00ed pom\u011br AMP\/ATP. Tato dvoustup\u0148ov\u00e1 konverze \u010din\u00ed slou\u010deninu zaj\u00edmavou pro enzymologick\u00fd a kin\u00e1zov\u011b orientovan\u00fd laboratorn\u00ed v\u00fdzkum. V d\u016fsledku toho se AICAR pou\u017e\u00edv\u00e1 jako modelov\u00e1 slou\u010denina a referen\u010dn\u00ed l\u00e1tka ve v\u011bdeck\u00e9m v\u00fdzkumu.<\/p>\n<h2>Oblasti v\u00fdzkumu<\/h2>\n<p>V laboratorn\u00edm kontextu se AICAR vyskytuje mimo jin\u00e9 v n\u00e1sleduj\u00edc\u00edch oblastech v\u00fdzkumu:<\/p>\n<ul>\n<li>Enzymologick\u00fd v\u00fdzkum alosterick\u00e9 regulace AMP-aktivovan\u00e9 proteinkin\u00e1zy a role nukleotidov\u011b v\u00e1zaj\u00edc\u00ed \u03b3-podjednotky in vitro.<\/li>\n<li>V\u00fdzkum fosforylace AICAR adenosinkin\u00e1zou a tvorby a degradace nukleotidu ZMP v bun\u011b\u010dn\u00fdch modelech.<\/li>\n<li>Studie de novo biosynt\u00e9zy purin\u016f, ve kter\u00e9 je ribonukleotid AICAR p\u0159irozen\u00fdm meziproduktem t\u00e9to dr\u00e1hy.<\/li>\n<li>Modelov\u00e9 studie substr\u00e1t\u016f fosforylace AMPK v downstreamu, jako je acetyl-CoA karboxyl\u00e1za, kter\u00e1 slou\u017e\u00ed jako parametr pro ode\u010det kin\u00e1zov\u00e9 aktivity v bun\u011b\u010dn\u00fdch kultiva\u010dn\u00edch syst\u00e9mech.<\/li>\n<li>V\u00fdvoj a validace analytick\u00fdch metod (HPLC, LC-MS) s pou\u017eit\u00edm AICAR jako referen\u010dn\u00edho standardu pro nukleosidov\u00e9 analogy.<\/li>\n<li>Studie stability a rozpustnosti lyofilizovan\u00fdch nukleosidov\u00fdch analog\u016f za kontrolovan\u00fdch podm\u00ednek.<\/li>\n<\/ul>\n<p>Ka\u017ed\u00e1 z t\u011bchto aplikac\u00ed zahrnuje kontrolovan\u00fd laboratorn\u00ed nebo preklinick\u00fd modelov\u00fd v\u00fdzkum.<\/p>\n<h2>AICAR v r\u00e1mci na\u0161eho v\u00fdzkumn\u00e9ho rozsahu<\/h2>\n<p>V r\u00e1mci na\u0161\u00ed produktov\u00e9 \u0159ady spad\u00e1 AICAR do kategorie lyofilizovan\u00fdch experiment\u00e1ln\u00edch slou\u010denin ve form\u011b lahvi\u010dek. V\u00fdzkumn\u00edci pracuj\u00edc\u00ed s touto kategori\u00ed \u010dasto kombinuj\u00ed slou\u010deninu s jin\u00fdmi lyofilizovan\u00fdmi l\u00e1tkami, kter\u00e9 jsou studov\u00e1ny prost\u0159ednictv\u00edm jejich vlastn\u00edho biochemick\u00e9ho c\u00edle. Zat\u00edmco AICAR se zam\u011b\u0159uje na nukleotidov\u011b \u0159\u00edzen\u00fd kin\u00e1zov\u00fd syst\u00e9m, jin\u00e9 slo\u017eky ve stejn\u00e9 produktov\u00e9 \u0159ad\u011b byly vybr\u00e1ny tak, aby pokr\u00fdvaly c\u00edle v\u00e1zan\u00e9 na receptory nebo zprost\u0159edkovan\u00e9 peptidy. Tyto slou\u010deniny sd\u00edlej\u00ed lyofilizovanou formu lahvi\u010dek, ale z\u00e1sadn\u011b se li\u0161\u00ed molekul\u00e1rn\u00ed t\u0159\u00eddou a zkouman\u00fdm mechanismem.<\/p>\n<h2>Specifikace<\/h2>\n<table>\n<thead>\n<tr>\n<th>Specifikace<\/th>\n<th>Hodnota<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Ochutnat<\/td>\n<td>AICAR<\/td>\n<\/tr>\n<tr>\n<td>Synonyma<\/td>\n<td>Akadesin; AICA ribosid; 5-amino-1-\u03b2-D-ribofuranosylimidazol-4-karboxamid; GP-1-110; NSC-105823<\/td>\n<\/tr>\n<tr>\n<td>\u010c\u00edslo CAS<\/td>\n<td>2627-69-2<\/td>\n<\/tr>\n<tr>\n<td>Molekul\u00e1rn\u00ed vzorec \/ hmotnost<\/td>\n<td>C<sub>9<\/sub>H<sub>14<\/sub>N<sub>4<\/sub>O<sub>5<\/sub> \/ 258,23 Da<\/td>\n<\/tr>\n<tr>\n<td>PubChem CID<\/td>\n<td>17513<\/td>\n<\/tr>\n<tr>\n<td>T\u0159\u00edda<\/td>\n<td>Mal\u00e1 molekula, nukleosidov\u00fd analog (nepeptid)<\/td>\n<\/tr>\n<tr>\n<td>Formul\u00e1\u0159<\/td>\n<td>Lyofilizovan\u00fd pr\u00e1\u0161ek v lahvi\u010dce<\/td>\n<\/tr>\n<tr>\n<td>Mno\u017estv\u00ed na lahvi\u010dku<\/td>\n<td>50 mg<\/td>\n<\/tr>\n<tr>\n<td>Skladov\u00e1n\u00ed<\/td>\n<td>Uchov\u00e1vejte v chladni\u010dce, chra\u0148te p\u0159ed sv\u011btlem a vlhkost\u00ed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Tvar, manipulace a skladov\u00e1n\u00ed<\/h2>\n<p>AICAR se dod\u00e1v\u00e1 jako lyofilizovan\u00fd pr\u00e1\u0161ek se standardizovan\u00fdm mno\u017estv\u00edm 50 mg na lahvi\u010dku, uzav\u0159en\u00fd pry\u017eovou z\u00e1tkou s hlin\u00edkov\u00fdm uz\u00e1v\u011brem. Na rozd\u00edl od pevn\u00e9 tablety se tento lyofiliz\u00e1t rozpou\u0161t\u00ed ve vhodn\u00e9m rozpou\u0161t\u011bdle v laboratorn\u00edm prost\u0159ed\u00ed p\u0159ed proveden\u00edm analytick\u00fdch nebo mechanick\u00fdch prac\u00ed; lyofilizovan\u00fd stav slou\u017e\u00ed p\u0159edev\u0161\u00edm k zaji\u0161t\u011bn\u00ed stability b\u011bhem skladov\u00e1n\u00ed a p\u0159epravy.<\/p>\n<p>Lahvi\u010dku skladujte v chladni\u010dce v p\u016fvodn\u00edm obalu, chr\u00e1n\u011bn\u00e9m p\u0159ed p\u0159\u00edm\u00fdm sv\u011btlem a vlhkost\u00ed. S l\u00e1tkou manipulujte se standardn\u00edmi laboratorn\u00edmi opat\u0159en\u00edmi: pracujte v \u010dist\u00e9m prost\u0159ed\u00ed, pou\u017e\u00edvejte vhodn\u00e9 osobn\u00ed ochrann\u00e9 prost\u0159edky a zabra\u0148te k\u0159\u00ed\u017eov\u00e9 kontaminaci s jin\u00fdmi v\u00fdzkumn\u00fdmi materi\u00e1ly. Uchov\u00e1vejte obal mimo dosah neopr\u00e1vn\u011bn\u00fdch osob.<\/p>\n<h2>Slo\u017een\u00ed a laboratorn\u00ed v\u00fdsledky<\/h2>\n<p>U t\u00e9to slou\u010deniny je udr\u017eov\u00e1na kontrolovan\u00e1 \u010distota \u2265 99 % (HPLC), jak je obvykl\u00e9 u lyofilizovan\u00fdch slou\u010denin ve form\u011b lahvi\u010dek. Lahvi\u010dka obsahuje jeden lyofiliz\u00e1t bez p\u0159idan\u00fdch pomocn\u00fdch l\u00e1tek.<\/p>\n<p>P\u0159ehled dostupn\u00e9 analytick\u00e9 dokumentace naleznete na na\u0161ich <a href=\"https:\/\/lumopeptides.com\/labresultaten\/\" target=\"_blank\" rel=\"noopener\">str\u00e1nka s v\u00fdsledky laboratorn\u00edch test\u016f<\/a>Zpr\u00e1vy se shroma\u017e\u010fuj\u00ed centr\u00e1ln\u011b tam, abyste mohli data za\u010dlenit do vlastn\u00edch v\u00fdzkumn\u00fdch z\u00e1znam\u016f.<\/p>\n<h2>\u010casto kladen\u00e9 ot\u00e1zky<\/h2>\n<p><strong>Do kter\u00e9 t\u0159\u00eddy l\u00e1tek pat\u0159\u00ed AICAR?<\/strong><br \/>AICAR je mal\u00e1 syntetick\u00e1 molekula z t\u0159\u00eddy nukleosidov\u00fdch analog\u016f, slo\u017een\u00e1 z imidazol-4-karboxamidov\u00e9ho j\u00e1dra a rib\u00f3zov\u00e9 jednotky. Nejedn\u00e1 se o peptid, a proto neobsahuje \u017e\u00e1dnou aminokyselinovou sekvenci.<\/p>\n<p><strong>Jak\u00e1 je role ZMP ve v\u00fdzkumu?<\/strong><br \/>V bun\u011b\u010dn\u00fdch modelech je AICAR fosforylov\u00e1n adenosinkin\u00e1zou na ribonukleotid ZMP. Tento nukleotid je strukturn\u011b podobn\u00fd AMP, a proto je pova\u017eov\u00e1n za mimetikum AMP; je \u00fast\u0159edn\u00edm bodem mechanistick\u00e9ho v\u00fdzkumu alosterick\u00e9 aktivace AMPK in vitro.<\/p>\n<p><strong>V jak\u00e9 form\u011b je dod\u00e1v\u00e1no p\u0159ipojen\u00ed?<\/strong><br \/>Jako lyofilizovan\u00fd pr\u00e1\u0161ek o hmotnosti 50 mg v uzav\u0159en\u00e9 lahvi\u010dce, ur\u010den\u00fd k rozpu\u0161t\u011bn\u00ed ve vhodn\u00e9m rozpou\u0161t\u011bdle p\u0159ed analytick\u00fdm pou\u017eit\u00edm.<\/p>\n<p><strong>Jak m\u00e1m skladovat lahvi\u010dku?<\/strong><br \/>Skladujte v chladni\u010dce, chr\u00e1n\u011bn\u00e9 p\u0159ed sv\u011btlem a vlhkost\u00ed, nejl\u00e9pe neotev\u0159en\u00e9 v p\u016fvodn\u00edm obalu a bez opakovan\u00fdch teplotn\u00edch zm\u011bn.<\/p>","protected":false},"excerpt":{"rendered":"<p><strong data-start=\"740\" data-end=\"802\">AICAR \u2013 Molekul\u00e1rn\u00ed slou\u010denina pro v\u00fdzkumn\u00e9 aplikace<\/strong><br data-start=\"802\" data-end=\"805\" \/>AICAR (5-aminoimidazol-4-karboxamid ribonukleotid) je syntetick\u00e1 slou\u010denina pou\u017e\u00edvan\u00e1 v laboratorn\u00edm a preklinick\u00e9m v\u00fdzkumu. Molekula se pou\u017e\u00edv\u00e1 ke studiu chemick\u00fdch vlastnost\u00ed, molekul\u00e1rn\u00ed stability a interakc\u00ed s intracelul\u00e1rn\u00edmi procesy za kontrolovan\u00fdch podm\u00ednek. AICAR nen\u00ed spot\u0159ebn\u00ed produkt a nen\u00ed ur\u010den pro l\u00e9ka\u0159sk\u00e9 ani fyziologick\u00e9 aplikace.<\/p>","protected":false},"featured_media":3268,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[120,121],"product_tag":[],"class_list":["post-2862","product","type-product","status-publish","has-post-thumbnail","product_cat-longevity-onderzoek","product_cat-peptides","first","instock","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/pevropeptides.com\/cs\/wp-json\/wp\/v2\/product\/2862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pevropeptides.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/pevropeptides.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/pevropeptides.com\/cs\/wp-json\/wp\/v2\/comments?post=2862"}],"version-history":[{"count":1,"href":"https:\/\/pevropeptides.com\/cs\/wp-json\/wp\/v2\/product\/2862\/revisions"}],"predecessor-version":[{"id":2936,"href":"https:\/\/pevropeptides.com\/cs\/wp-json\/wp\/v2\/product\/2862\/revisions\/2936"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pevropeptides.com\/cs\/wp-json\/wp\/v2\/media\/3268"}],"wp:attachment":[{"href":"https:\/\/pevropeptides.com\/cs\/wp-json\/wp\/v2\/media?parent=2862"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/pevropeptides.com\/cs\/wp-json\/wp\/v2\/product_brand?post=2862"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/pevropeptides.com\/cs\/wp-json\/wp\/v2\/product_cat?post=2862"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/pevropeptides.com\/cs\/wp-json\/wp\/v2\/product_tag?post=2862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}